论文部分内容阅读
目的:观察拉米夫定联合阿德福韦酯治疗慢性乙型肝炎患者的临床疗效及安全性。方法:选取2008年1月到2011年12月收治的HBeAg阳性慢性乙型肝炎患者110例,分组为单药组和联合组,单药组服用拉米夫定100 mg/d,联合组服用拉米夫定100 mg/d和阿德福韦酯10 mg/d,观察两组患者治疗96周的疗效及不良反应。结果:治疗96周后,联合组的HBV-DNA应答率、ALT复常率、HBeAg阴转率、HBeAg血清学转换率分别为96.4%、94.5%、61.8%和41.9%,远高于单药组的72.7%、83.7%、45.3%和34.5%(P<0.05),两组治疗期间仅见轻度不良反应。单药组出现12例病毒学突破,联合组未见。结论:HBeAg阳性的慢性乙型肝炎患者,使用拉米夫定联合阿德福韦酯治疗可以提高临床疗效,降低病毒耐药率,具有良好的安全性。
Objective: To observe the clinical efficacy and safety of lamivudine combined with adefovir dipivoxil in the treatment of chronic hepatitis B patients. Methods: A total of 110 patients with HBeAg-positive chronic hepatitis B who were admitted to our hospital from January 2008 to December 2011 were selected as the single drug group and the combination group. The single drug group took 100 mg lamivudine per day, Mifuding 100 mg / d and adefovir dipivoxil 10 mg / d, the two groups of patients treated for 96 weeks of efficacy and adverse reactions. Results: After 96 weeks treatment, the HBV-DNA response rate, ALT normalization rate, HBeAg negative conversion rate and HBeAg seroconversion rate were 96.4%, 94.5%, 61.8% and 41.9% in the combined group (72.7%, 83.7%, 45.3% and 34.5%, P <0.05). Only mild adverse reactions were observed in the two groups. Twelve virological breakthroughs occurred in the single drug group, but no one in the combined group. Conclusion: HBeAg-positive patients with chronic hepatitis B, lamivudine combined with adefovir dipivoxil treatment can improve clinical efficacy, reduce the rate of virus resistance, with good safety.